Abstract

Aim: The neurological disorder known as normal pressure hydrocephalus (NPH), which has an unknown cause, may be treatable, and is defined by a clinical triad of symptoms. A phenomenon known as dementia refers to a decline in cognitive performance that goes beyond what may be anticipated from the typical effects of biological aging. The symptomatic similarity between these two diseases causes problems in diagnosis. The objective of our study was to compare the concentrations of IL-17A, IL-17F, IL-34, and CXCL13 in the cerebrospinal fluid (CSF) of patients with NPH and dementia for an informative laboratory diagnosis.

Methods: The study included NPH and dementia cases (n=7, n=5, respectively) taken from the patients’s CSF sample by lumbar puncture (LP). The levels of IL-17A, IL-17F, IL-34, and CXCL13 were measured in the CSF of patients' with NPH and dementia by enzyme-linked assay (ELISA) and compared between the two different groups.

Results: There was no difference in age between the NPH and dementia groups (p=0.5). There was no statistically significant difference was found in IL-17A (p=0.7), IL-34 (p=0.9), and CXCL13 (p=0.2) in the inflammatory marker analysis in the CSF. The groups had a statistically significant difference in IL-17F (p=0.04).

Conclusion: IL-17F can be an important laboratory marker used in the differential diagnosis of NPH and dementia.

Keywords: NPH, Dementia, IL-17A, IL-17F, IL-34, CXCL13

Copyright and license

Copyright © 2024 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Karabörk Ş, Çelik H, Aydın Türkoğlu Ş. Does cerebrospinal fluid IL-17F distinguish normal pressure hydrocephalus from dementia?. Northwestern Med J. 2024;4(1):7-13. https://doi.org/10.54307/2024.NWMJ.81

References

  1. Rauf A, Badoni H, Abu-Izneid T, et al. Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases. Molecules. 2022; 27(10): 3194. https://doi.org/10.3390/molecules27103194
  2. Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020; 9(1): 42. https://doi.org/10.1186/s40035-020-00221-2
  3. Schain M, Kreisl WC. Neuroinflammation in Neurodegenerative Disorders-a Review. Curr Neurol Neurosci Rep. 2017; 17(3): 25. https://doi.org/10.1007/s11910-017-0733-2
  4. Bordoni M, Scarian E, Rey F, et al. Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach. Int J Mol Sci. 2020; 21(9): 3243. https://doi.org/10.3390/ijms21093243
  5. Passos-Neto CEB, Lopes CCB, Teixeira MS, Studart Neto A, Spera RR. Normal pressure hydrocephalus: an update. Arq Neuropsiquiatr. 2022; 80(5 Suppl 1): 42-52. https://doi.org/10.1590/0004-282X-ANP-2022-S118
  6. Zhang XJ, Guo J, Yang J. Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus. Neuroimmunology and Neuroinflammation. 2020; 7(2): 109-19. https://doi.org/10.20517/2347-8659.2019.018
  7. Sosvorova L, Vcelak J, Mohapl M, Vitku J, Bicikova M, Hampl R. Selected pro- and anti-inflammatory cytokines in cerebrospinal fluid in normal pressure hydrocephalus. Neuro Endocrinol Lett. 2014; 35(7): 586-93.
  8. Lolansen SD, Rostgaard N, Oernbo EK, Juhler M, Simonsen AH, MacAulay N. Inflammatory Markers in Cerebrospinal Fluid from Patients with Hydrocephalus: A Systematic Literature Review. Dis Markers. 2021; 2021: 8834822. https://doi.org/10.1155/2021/8834822
  9. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA. 2019; 322(16): 1589-99. https://doi.org/10.1001/jama.2019.4782
  10. Schindler SE. Fluid Biomarkers in Dementia Diagnosis. Continuum (Minneap Minn). 2022; 28(3): 822-33. https://doi.org/10.1212/CON.0000000000001083
  11. Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013; 2013: 480739. https://doi.org/10.1155/2013/480739
  12. Fakhoury M. Role of Immunity and Inflammation in the Pathophysiology of Neurodegenerative Diseases. Neurodegener Dis. 2015; 15(2): 63-9. https://doi.org/10.1159/000369933
  13. Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023; 23(1): 38-54. https://doi.org/10.1038/s41577-022-00746-9
  14. Chen J, Liu X, Zhong Y. Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases. Front Aging Neurosci. 2020; 12: 566922. https://doi.org/10.3389/fnagi.2020.566922
  15. Baghdadi M, Umeyama Y, Hama N, et al. Interleukin-34, a comprehensive review. J Leukoc Biol. 2018; 104(5): 931-51. https://doi.org/10.1002/JLB.MR1117-457R
  16. Benallegue N, Kebir H, Alvarez JI. Neuroinflammation: Extinguishing a blaze of T cells. Immunol Rev. 2022; 311(1): 151-76. https://doi.org/10.1111/imr.13122
  17. Gaetani L, Paolini Paoletti F, Bellomo G, et al. CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends Pharmacol Sci. 2020; 41(12): 1023-37. https://doi.org/10.1016/j.tips.2020.09.011
  18. Trolese MC, Mariani A, Terao M, et al. CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis. EBioMedicine. 2020; 62: 103097. https://doi.org/10.1016/j.ebiom.2020.103097
  19. Nakajima M, Yamada S, Miyajima M, et al. Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus. Neurol Med Chir (Tokyo). 2021; 61(2): 63-97. https://doi.org/10.2176/nmc.st.2020-0292
  20. Pink J, O'Brien J, Robinson L, Longson D; Guideline Committee. Dementia: assessment, management and support: summary of updated NICE guidance. BMJ. 2018; 361: k2438. https://doi.org/10.1136/bmj.k2438
  21. Hussain M, Kumar P, Khan S, Gordon DK, Khan S. Similarities Between Depression and Neurodegenerative Diseases: Pathophysiology, Challenges in Diagnosis and Treatment Options. Cureus. 2020; 12(11): e11613. https://doi.org/10.7759/cureus.11613
  22. Cuff SM, Merola JP, Twohig JP, Eberl M, Gray WP. Toll-like receptor linked cytokine profiles in cerebrospinal fluid discriminate neurological infection from sterile inflammation. Brain Commun. 2020; 2(2): fcaa218. https://doi.org/10.1093/braincomms/fcaa218
  23. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019; 50(4): 892-906. https://doi.org/10.1016/j.immuni.2019.03.021